Federal Register / Vol. 76, No. 44 / Monday, March 7, 2011 / Notices 12361 

information, or any non-public 

corporate or trade association 

information, such as trade secrets or 

other proprietary information. 

FOR FURTHER INFORMATION CONTACT: Roy 

Fleming, Sc.D., CDC/NIOSH, 1600 

Clifton Road, NE., MS–E20, Atlanta, 

Georgia 30333, Toll free 1–866–426– 

3673, e-mail: nioshdocket@cdc.gov. 

Dated: February 28, 2011. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2011–5111 Filed 3–4–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Determine of 

the Benefits of Work and/or School 

Exclusion to Respiratory Illness in 

Decreasing Influenza Transmission, 

Funding Opportunity Number (FOA) 

CK11–007, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 8 a.m.–5 p.m., May 2, 2011 

(Closed). 

Place: Sheraton Gateway Hotel Atlanta 

Airport, 1900 Sullivan Road, Atlanta, Georgia 

30337, Telephone: (770) 997–1100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: [The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Determine of the Benefits of 

work and/or School Exclusion to Respiratory 

Illness in Decreasing Influenza 

Transmission’’] 

Contact Person for More Information: Dr. 

Amy Yang, Scientific Review Officer, CDC, 

1600 Clifton Road, NE., Mailstop E60, 

Atlanta, Georgia 30333, Telephone: (404) 

498–2733. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 25, 2011. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2011–5102 Filed 3–4–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH 134–A] 

Request for Information: Update of 

NIOSH Nanotechnology Strategic Plan 

for Research and Guidance 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of public comment 

period. 

SUMMARY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) seeks 

comment on the types of hazard 

identification and risk management 

research that should be considered for 

updating the NIOSH 2009 

nanotechnology strategic plan. 

Public Comment Period: Comments 

must be received by April 15, 2011. 

ADDRESSES: Written comments, 

identified by docket number NIOSH 

134–A, may be submitted by any of the 

following ways: 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C–34, 4676 

Columbia Parkway, Cincinnati, Ohio 

45226. 

• Facsimile: (513) 533–8285. 

• E-mail: nioshdocket@cdc.gov. 

All information received in response 

to this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, 4676 Columbia Parkway, 

Room 109, Cincinnati, Ohio 45226. A 

complete electronic docket containing 

all comments submitted will be 

available thirty days after the public 

comment period on the NIOSH Web 

page at http://www.cdc.gov/niosh/ 

docket, and comments will be available 

in writing by request. NIOSH includes 

all comments received without change 

in the docket, including any personal 

information provided. All electronic 

comments should be formatted as 

Microsoft Word. Please make reference 

to docket number NIOSH 134–A. 

Background: Since 2004, the National 

Institute for Occupational Safety and 

Health (NIOSH) of the Centers for 

Disease Control and Prevention (CDC) 

has pioneered research on the 

toxicological properties and 

characteristics of nanoparticles. This 

research has involved characterizing 

occupationally relevant nanoparticles 

for predicting whether these particles 

pose a risk of adverse health effects and 

for providing guidance on controlling 

workplace exposures. In September 

2005, NIOSH developed a strategic plan 

to further guide the Institute in 

identifying and prioritizing 

nanotechnology research. In 2009 this 

strategic plan [http://www.cdc.gov/ 

niosh/topics/nanotech/strat_plan.html] 

was updated based on knowledge 

gained from results of ongoing NIOSH 

research [see Progress Toward Safe 

Nanotechnology in the Workplace; A 

Report from the NIOSH Nanotechnology 

Research Center http://www.cdc.gov/ 

niosh/docs/2007–123/] and from 

stakeholder input. 

NIOSH would like to build on the 

accomplishments of ongoing research 

[see http://www.cdc.gov/niosh/docs/

2010–104/] to develop strategic research 

goals and objectives through 2015. 

NIOSH has identified 10 critical 

research areas for nanotechnology 

research and communication. These 10 

critical research areas are (1) toxicity 

and internal dose, (2) measurement 

methods, (3) exposure assessment, (4) 

epidemiology and surveillance, (5) risk 

assessment, (6) engineering controls and 

personal protective equipment (PPE), (7) 

fire and explosion safety, (8) 

recommendations and guidance, (9) 

communication and information, and 

(10) applications. 

NIOSH is considering focusing the 

overarching strategic research goals for 

these critical areas on 5 key goals: (1) 

Provide guidance to protect workers, (2) 

alert workers, employers, governments, 

and the public about possible new 

hazards, (3) assess the hazards of 

nanomaterials and the risks to workers, 

(4) help workers by assessing and 

implementing exposure registries, and 

(5) assess the level of protection 

practiced in US workplaces. 

NIOSH requests comment on how 

research in these 10 critical areas and 

the 5 overarching goals can be 

enhanced. Examples of requested 

information include, but are not limited 

to: 

(1) The need for toxicity evaluation 

and/or workplace exposure 

characterization of engineered 

nanoparticles not currently being 

studied*. 


srobinson on DSKHWCL6B1PROD with NOTICES